	US 11,959,486 B2
	Stable liquid formulation of AMG 416 (etelcalcetide)
Derek Maclean, Los Altos, CA (US); and Qun Yin, Palo Alto, CA (US)
Assigned to Amgen Inc., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Aug. 11, 2021, as Appl. No. 17/400,044.
Application 17/400,044 is a continuation of application No. 16/430,322, filed on Jun. 3, 2019, granted, now 11,162,500.
Application 16/430,322 is a continuation of application No. 15/802,390, filed on Nov. 2, 2017, granted, now 10,344,765, issued on Jul. 9, 2019.
Application 15/802,390 is a continuation of application No. 14/908,481, granted, now 9,820,938, issued on Nov. 21, 2017, previously published as PCT/US2014/044622, filed on Jun. 27, 2014.
Claims priority of provisional application 61/840,618, filed on Jun. 28, 2013.
Prior Publication US 2022/0042515 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/08 (2019.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/12 (2006.01); A61P 3/00 (2006.01); A61P 3/14 (2006.01); A61P 5/00 (2006.01); A61P 5/18 (2006.01); A61P 43/00 (2006.01); F01D 15/10 (2006.01); F04D 25/06 (2006.01)

CPC F04D 25/0606 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 38/08 (2013.01); A61K 47/12 (2013.01); F01D 15/10 (2013.01)]

13 Claims

1. A composition, comprising:

etelcalcetide in a liquid formulation comprising water, wherein the formulation has a pH of 2.0 to 5.0 and wherein etelcalcetide is present at a concentration of between about 0.5 mg/mL to about 15 mg/mL.